CEACAM5 and adenocarcinoma: The use of CEA, CA125, and CA199 alone or in combination was reported to help in making decisions for digestive tract tumors or adenocarcinomas as prognostic indicators or in monitoring therapeutic effects [37–41], while the use of serological indications alone is insufficient for both sensitivity and specificity.